A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx ® in Healthy Chinese Male Subjects.
Feng YaoChenguang WangJie DingQian ZhangLiang ZhengQin ZhangTianshu YangXunmin ZhangYong ShanSheng HouHao WangRenpeng ZhouWei HuPublished in: Drug design, development and therapy (2024)
The trial was registered on Clinicaltrials.gov (Identifier No. NCT05734482) and Chinadrugtrials.org.cn (Identifier No. CTR20230105).